Rising lymphocytic leukemia to augment Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market Growth

 

Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market

Global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market, By Type (IgG, IgA and IgM) By Disease Indication (COVID-19, Primary Immunodeficiency Disease, Immune-mediated Thrombocytopenia, Kawasaki Disease, B Chronic lymphocytic Leukemia(B-CLL) and Others By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2022 – 2030

The global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market is estimated to be valued at US$ 43,205.8 million in 2020 and is expected to exhibit a CAGR of 12.7 % over the forecast period as highlighted in a new report published by Coherent Market Insights.

Market Overview

Human immunoglobulin for intravenous injection (IVIG) has the ability of proving passive resistance and anti-infection, immunomodulatory impact which results in better therapy and prediction of serious inflammation such as COVID-19. The IgG antigens extracted from recovered individuals of COVID- 19 are known to increase the immune response in recent infected patients, resulting a decrease in the time of treatment.

Covid-19 Impact Analysis:

Key players involved in the growth of global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market are ADMA Biologics, Inc., Takeda Pharmaceutical Company Limited, Hualan Biological Engineering Inc,, Baxter International Inc., CSL Behring, Bayer AG, Grifols, S.A., Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd., China Biologic Products, Inc., Boya Bio-Pharmaceutical Group Co., Ltd., Octapharma AG, Shanghai RAAS Blood Products Co., Ltd., and Sinopharm Group Co., Ltd.

Market Key Drivers:

The increasing prevalence of chronic lymphocytic leukemia, and demand for immune globulin products is expected to boost global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market. For instance, as per American Cancer Society over 60,530 new cases of leukemia were diagnosed in the U.S in 2020 out of which 21,040 new cases were chronic lymphocytic leukemia (CLL).

Rising adoption of inorganic growth strategies and collaborations is projected to propel the growth of global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market. For instance, in January 2020, ADMA Biologics, Inc., entered a 5-year production and supply agreement with a partner to generate and sell plasma-derived intermediate fractions from ADMA’s Immune Globulin production process. 

Covid-19 Impact Analysis:

The COVID-19 outbreak positively affected the growth of the global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market as it is expected to rise the demand for human immunoglobulin (pH4) for intravenous injection. These immunoglobulin antibodies are extracted from the patients who have overcome Covid-19.  All these factors propelled the market growth.

Key Takeaways:

The global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market is expected to exhibit a CAGR of 12.7 % during the forecast period owing to the rising Covid-19 cases. For instance, as per WHO, in May 3, 2023 around 765,222,932 confirmed cases of COVID-19 has been recorded.

Among regions, North America, Asia Pacific and Europe anticipated to witness robust growth in the global Human Immunoglobulin (pH4) for Intravenous Injection (COVID-19) Market due to rising demand of IG products, rising prevalence of chronic diseases and increasing growth of key players. For instance, on August 12, 2019, the USFDA stated that necessity for immune globulin products has increased in recent years.